India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
Zacks Investment Research on MSN10d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
GSK'227 targets B7-H3 ... General Medicine sales grew 6% in the year, and this was largely driven by Trelegy, up 27% with strong demand across all regions, strengthening its position as the ...
GSK reported Q4 sales of $10.40B ... General Medicines sales rose by 1% to 2.61 billion pounds. Trelegy (asthma drug) sales reached 669 million pounds, up 14%. The company reported core EPS ...
GSK plc GSK reported fourth-quarter 2024 core ... In this segment, the upside was primarily driven by solid sales growth of asthma inhaler Trelegy Ellipta across all regions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback